Latest news with #crinetics.com
Yahoo
11-04-2025
- Business
- Yahoo
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 8 @ 4:30 p.m. ET Domestic: 1-833-470-1428 International: 1-404-975-4839 Conference ID: CRNXQ1 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call. The webcast will be archived on the Investor Relations section of About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@ (858) 345-6340 Media: Natalie BadilloHead of Corporate Communications nbadillo@ (858) 345-6075
Yahoo
20-02-2025
- Business
- Yahoo
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL. TD Cowen 45th Annual Healthcare Conference Fireside chat on Monday, March 3, 2025 at 11:10 a.m. Eastern Time Webcast link HERE Leerink Global Healthcare Conference Fireside chat on Monday, March 10, 2025 at 4:20 p.m. Eastern Time Webcast link HERE The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist, that is currently in development for the treatment of congenital adrenal hyperplasia and Cushing's disease. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@ (858) 345-6340 Media: Natalie BadilloHead of Corporate Communications nbadillo@ (858) 345-6075
